The effect of severe COVID-19 infection on biochemical markers (FBS, HbA1C, FA, INS, C-Pep) in diabetic patients | [Anaesthesia, Pain and Intensive Care • 2024]

Author(s):

1. Marwah S. Yones: Clinical Laboratory Science Branch, College of Pharmacy, Mustansiriyah University,Baghdad,Iraq

2. Estabraq Al-Wasiti: Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University,Baghdad,Iraq

3. Abdul Hameed Al Qaseer: College of Medicine, Mustansiriyah University,Baghdad,Iraq

4. Hadel Kareem Al-Rubaiawi: College of Medicine, Mustansiriyah University,Baghdad,Iraq

Abstract:

Background & objective: Several studies have been conducted around the world on the impact of COVID-19 on people with diabetes mellitus (DM). Any acute illness can cause stress and increased inflammatory reactions, which increase sympathetic outflow and produce catecholamines, growth hormones, cortisol, and cytokines, all of which raise the risk and severity of complications from diabetes. Diabetes is a significant risk factor for the severity of COVID-19. We conducted this study to identify whether severe COVID-19 infection has any effect on the biomarkers, including fasting blood sugar (FBS), HbA1C, FA, INS, C-Pep, in individuals with DM. Methodology: This study was simultaneously conducted at Department of Chemistry and Biochemistry, College of Medicine of Al-Nahrain University, and Department of Medicine of Mustansiriyah University College of Medicine, Baghdad, Iraq. During the months of February and March 2022, 50 COVID-19 patients with diabetes and 50 COVID19 patients without diabetes were included in the study. The control group included 100 healthy, sexually identical people (age 50-80), collected under the supervision of the second supervisor from relatives and students of Mustansiriyah University, College of Medicine. Venous blood samples of 5 mL were taken from all participants and subjected to laboratory tests to detect the levels of the biomarkers. Results: Average FBS level in DM patients was 304.9 mg/dL, (range 132-545.9 mg/dL), which was remarkably higher than in non-DM patient groups (193.3 mg/dL), range (of 66.2-458). The DM patients' group had a significantly higher concentration of HbA1C (median = 6.70 mg/dL, range 5.2-8.1) than the non-DM patient group (median = 5.8, range 4.2-7.6) with a significant difference. Although The group of DM patients had significantly greater FA concentrations than the group of non-DM patients. In contrast, the median and range for insulin and c-peptide Displays nonsignificant differences for covid-19 patients (DM and non-DM), but it's significant with a control group. Conclusion: According to this study, COVID-19 patients with diabetes had greater biochemical indicator levels than non-diabetic people. Pre- and postprandial hyperglycemia and diabetic ketoacidosis were more common in COVID19 DM patients than in non-infected DM patients. We found that COVID-19 increased the severity risk for T2DM patients and glucose level is raised and progresses in a vicious cycle exacerbated by insulin resistance (IR) and decreased pancreatic b-cell function.

Page(s): 803-808

DOI: 10.35975/apic.v28i5.2553

Published: Journal: Anaesthesia, Pain and Intensive Care, Volume: 28, Issue: 5, Year: 2024

Keywords:

COVID19 , Diabetes mellitus , HbA1C , Diabetes mellitus , Covid19 , FBS , CPep , INS , FA

References:

[1] Soliman A,Nair AP,Al Masalamani MS,De Sanctis V,Khattab MAA,Alsaud AE .2020 .Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Biomed, 91(3) : 10214.

[2] Meo S,Alhowikan A,Al-Khlaiwi T,Meo I,Halepoto D,Iqbal M .2020 .Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERSCoV. Eur Rev Med Pharmacol Sci, 24(4) : 20379-9.

[3] Ahmed OJ,Al-Wasiti EA,Jamil D,Al-Aubaidy H D,Buzzetti R .2020 .Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev, 36(7) : 141-8.

[4] Sathish T,Kapoor N,Cao Y,Tapp RJ,Zimmet P .2021 .Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes Metab, 23(3) : 870-4.

[5] Chung MK,Karnik S,Saef J,Bergmann C,Barnard J,Lederman MM .2020 .SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine, 58 : 102907.

[6] Pal R,Bhansali A .2020 .diabetes mellitus and ACE2: the conundrum. Diabetes Res Clin Pract, 162 : .

[7] Michalakis K,Ilias I. .2020 .SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr, 04(4) : 469-71.

[8] Liu Z,Xiao X,Wei X,Li J,Yang J,Tan H,Virol J Med .2020 .Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. , 92(6) : 595-601.

[9] Al-Kuraishy HM,Al-Maiahy TJ,Al-Gareeb AI,Musa RA,Ali ZH .2020 .COVID-19 pneumonia in an Iraqi pregnant woman with preterm delivery. Asian Pac J Reprod, 10(3) : 282984-0500.

[10] Hadi A,Werge M,Kristiansen KT,Pedersen UG,Karstensen JG,Novovic S .2020 .Coronavirus disease-19 (COVID-19) associated with severe acute pancreatitis: case report on three family members. Pancreatology, 04(4) : 665-7.

[11] Mehta P,McAuley DF,Brown M,Sanchez E,Tattersall RS,Manson JJ .2020 .consider cytokine storm syndromes and immunosuppression. Lancet, 6736(20) : 30628-0.

[12] Caruso I,Di Molfetta S,Guarini F,Giordano F,Cignarelli A,Natalicchio A . .Reduction of hypoglycaemia, lifestyle modifications and psychological distress during lockdown. , : .

[13] Abdul-Hadi MH,Naji MT,Shams HA,Sami OM,Al-Harchan NAA,Al-Kuraishy HM .2020 .Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: The potential role of metformin and sitagliptin. Biomed Biotechnol Res J, 7(2) : 20.

[14] Albulescu R,Dima SO,Florea IR,Lixandru D,Serban AM,Aspritoiu VM .2020 .-19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis. Exp Ther Med, 20(6) : 194.

[15] El-Huneidi W,Hamad M,Taneera J .2021 .Expression of SARS-CoV2 receptor "ACE2" in human pancreatic β cells: to be or not to be. , 13(5-6) : 106-14.

[16] Zhao R,Li M,Song H,Chen J,Ren W,Feng Y .2020 .Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection in Patients With Coronavirus Disease 2019. Clin Infect Dis, 71(16) : 2066-72.

[17] Holt A,Mizrak I,Lamberts M,Madsen PL .2020 .Influence of inhibitors of the renin-angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients. J Hypertens, 38(8) : 1612-3.

[18] Sathish T,Cao Y .2021 .What is the role of admission HbA1c in managing COVID-19 patients?. , 13(3) : 13140-0407.

[19] Tavares Ribeiro R,Paula Macedo M,Filipe Raposo M .2016 .HbA1c, fructosamine, and glycated albumin in the detection of dysglycaemic conditions. Curr Diabetes Rev, 12(1) : 14-9.

[20] Robeva R,Petrova D,Elenkova A,Tankova T,Zacharieva S. .2022 .Cpeptide levels and glycemic indices in COVID-19 patients. , 10(1) : 418-24.

Citations

Downloads

Views